Teva Pharmaceutical Industries Limited (TEVA) & Antisense Therapeutics Limited (ANP.AX) Announce That ATL/TV1102, a Novel Drug for the Treatment of Relapsing Remitting Multiple Sclerosis (RRMS), Demonstrated Significant Reduction in Disease Activity  
6/30/2008 10:05:01 AM

JERUSALEM & MELBOURNE, Australia--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: Teva - News) and Antisense Therapeutics Ltd. (ASX: ANP - News) announced today that ATL/TV1102, a novel, anti-sense drug, significantly reduced disease activity in patients with relapsing-remitting multiple sclerosis (RRMS). A randomized, double-blind, placebo-controlled Phase IIa study met its primary endpoint showing a significant reduction by 54.4% (p=0.01) in cumulative number of new active lesions in patients taking ATL/TV1102 for 8 weeks, compared to placebo, as measured by magnetic resonance images (MRI).